Virtus KAR Health Sciences Inst holds a quantitatively derived Negative Morningstar Medalist Rating. The rating indicates the model sees limited potential for the strategy to outperform peers on a risk-adjusted basis over a full market cycle.
Virtus KAR Health Sciences Fund Institutional Class HLHIX
- NAV / 1-Day Return 30.32 / +0.23 %
- Total Assets 93.0M
-
Adj. Expense Ratio
1.050%
- Expense Ratio 1.050%
- Distribution Fee Level Above Average
- Share Class Type Institutional
- Category Health
- Investment Style Mid Blend
- Min. Initial Investment 1M
- Status Open
- TTM Yield 0.00
- Turnover 8%
USD | NAV as of Jul 22, 2026 | 1-Day Return as of Jul 22, 2026, 12:11 AM GMT+0
Morningstar’s Analysis HLHIX
Will HLHIX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 55.9
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Eli Lilly and Co | 13.32 | 12M | Healthcare |
McKesson Corp | 5.58 | 5M | Healthcare |
Vertex Pharmaceuticals Inc | 5.10 | 5M | Healthcare |
AbbVie Inc | 5.10 | 5M | Healthcare |
Merck & Co Inc | 5.06 | 5M | Healthcare |
Intuitive Surgical Inc | 4.81 | 4M | Healthcare |
West Pharmaceutical Services Inc | 4.41 | 4M | Healthcare |
IDEXX Laboratories Inc | 4.30 | 4M | Healthcare |
Mettler-Toledo International Inc | 4.21 | 4M | Healthcare |
The Cooper Companies Inc | 4.05 | 4M | Healthcare |
United States